Compare SEVN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEVN | SGMT |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.2M | 169.4M |
| IPO Year | 2008 | 2021 |
| Metric | SEVN | SGMT |
|---|---|---|
| Price | $8.27 | $5.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $11.50 | ★ $27.00 |
| AVG Volume (30 Days) | 91.8K | ★ 352.1K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $29,383,000.00 | $2,000,000.00 |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | $4,523.58 |
| P/E Ratio | $8.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.30 | $1.73 |
| 52 Week High | $13.02 | $11.41 |
| Indicator | SEVN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 41.75 |
| Support Level | N/A | $4.97 |
| Resistance Level | $8.95 | $6.49 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 3.03 | 7.02 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.